Neurocrine Biosciences reported third-quarter 2026 total revenues of $1.1 billion, representing 41% year-over-year growth, alongside GAAP net income of $207 million. The company also raised its full-year 2026 net sales guidance for INGREZZA to a range of $2.9 billion to $2.925 billion.
Total revenues for the third quarter of 2026 reached $1.1 billion, up 41% compared to $795 million in the third quarter of 2025.
INGREZZA net product sales were $801 million, leading management to raise full-year 2026 INGREZZA net sales guidance to $2.9 billion to $2.925 billion.
GAAP net income for the third quarter of 2026 was $207 million, or $1.96 per diluted share, compared to $210 million, or $2.04 per diluted share, in the prior-year period.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
From Neurocrine Biosciences's 10-Q and 10-K filings (SEC XBRL). YoY compares each quarter with the same quarter a year earlier; it is blank when the year-ago figure is missing or negative.
Annual results
Fiscal year
Revenue
Growth
EPS (diluted)
Growth
Net margin
FY2025
$2.86B
+21.4%
$4.67
+41.9%
16.7%
FY2024
$2.36B
+24.8%
$3.29
+33.2%
14.5%
FY2023
$1.89B
+26.8%
$2.47
+58.3%
13.2%
FY2022
$1.49B
+31.3%
$1.56
+69.6%
10.4%
FY2021
$1.13B
+8.4%
$0.92
-77.9%
7.9%
Frequently asked questions
When is Neurocrine Biosciences's next earnings date?
Neurocrine Biosciences has not announced a report date within the next three weeks. US companies usually report three to six weeks after each quarter ends; this page updates as soon as the date is on the calendar.
What did Neurocrine Biosciences earn last quarter?
For the quarter ended Sep 2026, Neurocrine Biosciences reported diluted EPS of $1.96 (-3.9% year over year) on revenue of $1.12B (+41.2%).
Where do these numbers come from?
Reported revenue, net income and EPS come from the company's own 10-Q and 10-K filings with the SEC (XBRL data). The report date and consensus estimate come from the Nasdaq earnings calendar.
Not investment advice. Figures can be restated by the company in later filings.